elbasvir targets the NS5A protein, which is crucial in viral replication, assembly, and secretion. By inhibiting NS5A, elbasvir prevents the production of new infectious virus particles and slows down the progression of the infection.
grazoprevir targets the NS3/4A protease, essential for viral replication and maturation. By inhibiting NS3/4A, grazoprevir blocks the cleavage of viral proteins and prevents the formation of new infectious virus particles.
Combining elbasvir and grazoprevir has a synergistic effect in treating chronic HCV infection. The two medications target different stages of the viral life cycle and can prevent the emergence of drug-resistant virus strains.
elbasvir/grazoprevir has a broad spectrum of activity against all six major genotypes of the HCV virus. It effectively treats treatment-naive and treatment-experienced patients, including those with compensated cirrhosis and HIV coinfection.